FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1347PDF: 217HTML: 133Appendix: 119 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
461PDF: 105 -
The key to fibrinolysis and thrombolysis
1686PDF: 521HTML: 261 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
749PDF: 24 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
912PDF: 119HTML: 121Supplementary: 78Appendix: 79 -
CO17 | Clinical relevance of isolated anti-phosphatidylserine/ prothrombin antibody positivity A. Hoxha1, P. Žigon2,3, L. Katja2,3, S. Čučnik2,4, Ž. Rotar2,5, S. Gavasso1, P. Zerbinati1, G. Gobbo1, P. Simioni1 | 1University of Padua, Internal Medicine Unit, Thrombotic and Hemorrhagic Centre, Department of Medicine-DIMED, Padua, Italy; 2University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 3University of Primorska, Faculty of Mathematics, Natural Sciences and Information Technologies, Koper, Slovenia; 4University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia; 5University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
635PDF: 13 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
643PDF: 21 -
CO-86 | A RARE CASE OF ACQUIRED HEMOPHILIA A ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
27PDF: 11 -
PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini1, C. Biasoli2, M. Bovara3, E. Gesuete1, A. Fusco1, C. Fantoni1, P. Pedrazzi2, R. Mancini3, M. Silingardi1 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; 2SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; 3Laboratorio Unico Metropolitano AUSL Bologna, Italy
640PDF: 17 -
CO11 | Oral anticoagulation with vitamin K antagonists in early childhood: a single centre-experience B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
704PDF: 23 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
490PDF: 110 -
PO10 | Clinical and laboratory features of long-Covid syndrome: a cross-sectional study of 1,337 Covid-19 survivors C. Ambaglio1, S. V. Benatti2, C. J. Tartari1,3, L. Russo1,3, S. Bolognini1,3, C. Ticozzi1, F. Schieppati1, V. Brusegan1, S. Venturelli2, L. Barcella1, M. Rizzi2, M. Marchetti1,3, A. Falanga1,3 | 1Department of Immunohematology and Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo; 2Division of Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo; 3Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
648PDF: 18 -
CO-85 | ACQUIRED HEMOPHILIA A IN LIVER CIRRHOSIS: BALANCING HEMOSTASIS BETWEEN HIGH HEMORRHAGIC AND THROMBOTIC RISKS N. Portesi, G. Martini | ASST Spedali Civili di Brescia, Italy
22PDF: 15 -
PO63 | Atypical venous thrombosis in young patient with systemic lupus erythematosus and high-risk APL profile: provoked or not? E. Marrone, A. Parisi, G. Di Monda, F. Gallucci, D. Morelli, C. Romano, U. Malgeri, D. D’Auria, P. Morella | Internal Medicine Unit 3, Cardarelli Hospital, Naples, Italy
599PDF: 22 -
CO35 | Bleeding phenotype characterization in patients with congenital bleeding disorders: a multigenic approach using next generation sequencing to identify coagulation-modulating variants C. Simion, L. Gianesello, C. Bulato, A. Benetti, E. Campello, A. Giannella, G. Ceolotto, E. Zanon, L. Spiezia, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
537PDF: 27 -
CO-83 | ACQUIRED FACTOR V DEFICIENCY IN A HIGH-THROMBOTIC-RISK PATIENT: DIAGNOSTIC DILEMMA AND SUCCESSFUL MANAGEMENT G. Gazzelli1, L. Banov1, Y. Azzanelli1, C. Vernarecci1, F. Marotta1, F. Giacopelli1, E. Cenni2, V. Agostini2, A.C. Molinari1 | 1IRCCS Istituto Giannina Gaslini, Italy; 2IRCSS AOM S. Martino, Genova, Italy
32PDF: 18 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
657PDF: 23 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
555PDF: 21 -
CO-73 | WHEN BLEEDING MIMICS THROMBOSIS: DIAGNOSTIC DELAY AND THROMBOTIC COMPLICATIONS IN ACQUIRED HEMOPHILIA A R. Tomasello1, M. Mattana1, S. Raso1, F. Schirò1, P. Polidori2, M.I. Di Lena3, F. La Gattuta4, M. Napolitano1 | 1Ematologia e malattie rare, PO Cervello di Palermo, Italy; 2Farmacia ospedaliera, PO Cervello di Palermo, Italy; 3Direzione medica, PO Cervello di Palermo, Italy; 4Radiologia interventistica, PO Villa Sofia di Palermo, Italy
28PDF: 8 -
PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
618PDF: 20 -
Influence of emicizumab on protein C-mediated clotting regulation
2647PDF: 439Supplementary Material: 136 -
CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry A. Napolitano1, L. Spiezia1, C. Samà1, A. Benetti1, G. Sinigiani2, L. De Michieli2, A. Cipriani2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; 2Department of Cardiothoracic and Vascular Sciences & Public Health, University Hospital of Padua, Italy
591PDF: 10 -
CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso1|2, M. Shima3, J.M. Staber4, Y.C. Chen5, F.J. López-Jaime6, M.C. Shen7, G. Ventriglia8, M. Takeyama9, C. Schmitt8, Y.S. Park10, A. Kiialainen8, N. Mizuno11, M. Niggli8, T. Miyake11, D. Matino12, T. Saito11, V. Jiménez-Yuste13, R. Kobayashi11, D. Hart14, K. Nogami15 | 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; 4Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; 5Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; 7Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; 10Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; 11Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; 12McMaster University, Hamilton, Ontario, Canada; 13La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; 14Roche Products Ltd, Welwyn Garden City, UK; 15Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
23PDF: 14 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
619PDF: 19 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
625PDF: 16 -
CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas1,2, M. Marchetti1,3, L. Russo1, C.J. Tartari1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca5, A. Falanga1,3 All on behalf of the Hypercan Investigators | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; 3School of Medicine and Surgery, University of Milan Bicocca, Italy; 4University Vita-Salute San Raffaele, Milan, Italy; 5Fondazione ARTET Onlus, Bergamo, Italy
630PDF: 14 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
615PDF: 15
1 - 33 of 33 items
